Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

By , in PR PR California on .

NEW YORK, Dec. 26, 2017 — WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on ARGS, OMER, RGLS, and RYTM which can be accessed for free by signing up to www.wallstequities.com/registration. Business Wire reported that the global Biotechnology market size was estimated at $369.62 billion in 2016, and is expected to reach $727.1 billion by 2025, according to Grand View Research. This morning, WallStEquities.com redirects investors' attention to four stocks in this space to monitor their recent performance: Argos Therapeutics Inc. (NASDAQ: ARGS), Omeros Corp. (NASDAQ: OMER), Regulus Therapeutics Inc. (NASDAQ: RGLS), and Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM). All you have to do is sign up today for this free limited time offer, click the link below. www.wallstequities.com/registration

Argos Therapeutics

Durham, North Carolina headquartered Argos Therapeutics Inc.'s stock finished last Friday's session 3.20% higher at $0.15. A total volume of 1.81 million shares was traded. The Company's shares are trading below their 50-day moving average by 7.35%. Additionally, shares of Argos Therapeutics, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have a Relative Strength Index (RSI) of 45.78.  

On November 28th, 2017, Argos Therapeutics (ARGS) announced that TKC Properties (TKC), the landlord of the facility in Durham County, NC that ARGS had previously intended to utilize as its primary manufacturing facility, has, with ARGS' full consent, successfully completed the sale of this facility to a third party. In connection with this transaction, ARGS has entered into a lease termination agreement with TKC pursuant to which the former received cash proceeds of approximately $1.8 million. Additionally, ARGS is no longer required to maintain restricted cash of approximately $0.7 million as a security deposit under the lease. Get the full research report on ARGS for free by clicking below at: www.wallstequities.com/registration/?symbol=ARGS

Omeros

On Friday, shares in Seattle, Washington-based Omeros Corp. ended the session 0.35% higher at $20.11. The stock recorded a trading volume of 390,600 shares. The Company's shares have gained 7.20% in the last one month and 102.72% on an YTD basis. The stock is trading 10.79% above its 50-day moving average and 8.32% above its 200-day moving average. Moreover, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 59.17.  

On December 12th, 2017, Omeros announced that the US FDA approved its supplemental new drug application, following review of efficacy and safety data from a pediatric clinical trial, expanding the indication for OMIDRIA (phenylephrine and ketorolac intraocular solution) 1% / 0.3% to include use in pediatric patients ages birth through 17 years old. OMIDRIA, used during cataract surgery or intraocular lens replacement, prevents intraoperative miosis (pupil constriction) and reduces postoperative pain. Access the free research report on OMER now by signing up at: www.wallstequities.com/registration/?symbol=OMER

Regulus Therapeutics

San Diego, California headquartered Regulus Therapeutics Inc.'s shares jumped 4.06%, closing the session at $1.00 with a total trading volume of 380,169 shares. The stock has gained 12.25% in the last one month. The stock is trading 0.89% below their 50-day moving average. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 55.91.  

On December 19th, 2017, Regulus Therapeutics announced that it has initiated the first-in-human Phase I study of RGLS4326 and completed dosing of the first cohort of healthy volunteers. RGLS4326 is in development for the treatment of autosomal dominant polycystic kidney disease. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RGLS at: www.wallstequities.com/registration/?symbol=RGLS

Rhythm Pharmaceuticals

Last Friday at the close, shares in Boston, Massachusetts-based Rhythm Pharmaceuticals Inc. recorded a trading volume of 138,069 shares. The stock ended the session 3.73% lower at $27.87. The Company's shares are trading above its 50-day and 200-day moving averages by 6.33% and 6.29%, respectively. Furthermore, shares of Rhythm Pharma, which develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the US, have an RSI of 50.72. Aspiring Member, please take a moment to register below for your free research report on RYTM at: www.wallstequities.com/registration/?symbol=RYTM

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-argos-therapeutics-omeros-regulus-therapeutics-and-rhythm-pharma-300575247.html

SOURCE Wall St. Equities

Related Links

http://www.wallstequities.com

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: